As new therapies for COVID-19 are tested over the coming months, cardiovascular health professionals working to optimize outcomes must be mindful of the “intricate interplay” between cardiovascular disease, the novel coronavirus and emerging or repurposed drug therapies.
They must remain so while simultaneously considering the concerns and views of healthcare workers, members of hospital/health system leadership and, not least, patients—whether the latter are infected or not.
That’s the view of a team of medical scholars who published a review paper online March 19 in the Journal of the American College of Cardiology.